Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Advanced Breast Cancer × elacestrant × Clear all

Phase

Status

Sponsor Class

OTHER 1 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Sarcoma, Endometrial Stromal 1 Recurrence 1 Perivascular Epithelioid Cell Neoplasms 1 Neoplasm Metastasis 1 Endometrial Neoplasms 1 ER+ Breast Cancer 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Cancer Patients 1 Advanced Breast Cancer 1 Adenosarcoma of the uterus 1

Interventions

Fulvestrant 5 olaparib 4 Letrozole 4 Aromatase Inhibitors 3 Anastrozole 3 trastuzumab deruxtecan 2 sacituzumab govitecan 2 pyrotinib 2 eribulin 2 dalpiciclib 2 Goserelin 2 Gonadotropin-Releasing Hormone 2 FCN-437c 2 Capecitabine 2 talazoparib 1 sonidegib 1 ribociclib 1 pembrolizumab 1 neratinib 1 liposomal doxorubicin 1 elacestrant 1 disitamab vedotin 1 ceralasertib 1 capivasertib 1 balixafortide 1 apatinib 1 abemaciclib 1 Vorinostat 1 Vinorelbine 1 Trastuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06382948 2026-04-03

ADELA

MedSIR

Phase 3 Recruiting

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡